Cargando…

Unilateral Tamoxifen-Induced Retinopathy as a Consequence of Breast Cancer Treatment—Multimodal Imaging Value

Tamoxifen is a drug used in breast cancer therapy, which inhibits the division of neoplastic cells targeting estrogen receptors. The drug is generally well-tolerated and its use does not cause serious side-effects. The standard dose of the drug is 20 mg once a day for 3 to 5 years. Available epidemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Szabelska, Paulina, Paczwa, Katarzyna, Ciszewska, Joanna, Różycki, Radosław, Gołębiewska, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093114/
https://www.ncbi.nlm.nih.gov/pubmed/37046468
http://dx.doi.org/10.3390/diagnostics13071250
_version_ 1785023508273692672
author Szabelska, Paulina
Paczwa, Katarzyna
Ciszewska, Joanna
Różycki, Radosław
Gołębiewska, Joanna
author_facet Szabelska, Paulina
Paczwa, Katarzyna
Ciszewska, Joanna
Różycki, Radosław
Gołębiewska, Joanna
author_sort Szabelska, Paulina
collection PubMed
description Tamoxifen is a drug used in breast cancer therapy, which inhibits the division of neoplastic cells targeting estrogen receptors. The drug is generally well-tolerated and its use does not cause serious side-effects. The standard dose of the drug is 20 mg once a day for 3 to 5 years. Available epidemiological data have shown that the incidence of ocular toxicity of tamoxifen ranges between 0.9% and 12.0% and increases with higher tamoxifen dose. A rare known complication of tamoxifen use is the development of retinopathy. We present a case of 57-year-old woman presented to an ophthalmologist with decreased visual acuity in her right eye. She has been treated with tamoxifen 20 mg daily for 7 years for breast cancer. Clinical examination and multimodal imaging methods help confirm the diagnosis of unilateral tamoxifen associated retinopathy (TAR). Optical coherence tomography angiography (OCTA) was crucial in the diagnostic process and differential diagnosis, especially in differentiating it from type 2 macular telangiectasias. The correct diagnosis of TAR is very important in deciding the treatment option of tamoxifen. Based on our diagnosis, the oncologist recommended another course of treatment. Tamoxifen therapy was discontinued and switched to letrozole 2.5 mg once a day. The patient attends ophthalmological examination regularly. Visual acuity, OCT and OCTA results remain stable.
format Online
Article
Text
id pubmed-10093114
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100931142023-04-13 Unilateral Tamoxifen-Induced Retinopathy as a Consequence of Breast Cancer Treatment—Multimodal Imaging Value Szabelska, Paulina Paczwa, Katarzyna Ciszewska, Joanna Różycki, Radosław Gołębiewska, Joanna Diagnostics (Basel) Interesting Images Tamoxifen is a drug used in breast cancer therapy, which inhibits the division of neoplastic cells targeting estrogen receptors. The drug is generally well-tolerated and its use does not cause serious side-effects. The standard dose of the drug is 20 mg once a day for 3 to 5 years. Available epidemiological data have shown that the incidence of ocular toxicity of tamoxifen ranges between 0.9% and 12.0% and increases with higher tamoxifen dose. A rare known complication of tamoxifen use is the development of retinopathy. We present a case of 57-year-old woman presented to an ophthalmologist with decreased visual acuity in her right eye. She has been treated with tamoxifen 20 mg daily for 7 years for breast cancer. Clinical examination and multimodal imaging methods help confirm the diagnosis of unilateral tamoxifen associated retinopathy (TAR). Optical coherence tomography angiography (OCTA) was crucial in the diagnostic process and differential diagnosis, especially in differentiating it from type 2 macular telangiectasias. The correct diagnosis of TAR is very important in deciding the treatment option of tamoxifen. Based on our diagnosis, the oncologist recommended another course of treatment. Tamoxifen therapy was discontinued and switched to letrozole 2.5 mg once a day. The patient attends ophthalmological examination regularly. Visual acuity, OCT and OCTA results remain stable. MDPI 2023-03-27 /pmc/articles/PMC10093114/ /pubmed/37046468 http://dx.doi.org/10.3390/diagnostics13071250 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Interesting Images
Szabelska, Paulina
Paczwa, Katarzyna
Ciszewska, Joanna
Różycki, Radosław
Gołębiewska, Joanna
Unilateral Tamoxifen-Induced Retinopathy as a Consequence of Breast Cancer Treatment—Multimodal Imaging Value
title Unilateral Tamoxifen-Induced Retinopathy as a Consequence of Breast Cancer Treatment—Multimodal Imaging Value
title_full Unilateral Tamoxifen-Induced Retinopathy as a Consequence of Breast Cancer Treatment—Multimodal Imaging Value
title_fullStr Unilateral Tamoxifen-Induced Retinopathy as a Consequence of Breast Cancer Treatment—Multimodal Imaging Value
title_full_unstemmed Unilateral Tamoxifen-Induced Retinopathy as a Consequence of Breast Cancer Treatment—Multimodal Imaging Value
title_short Unilateral Tamoxifen-Induced Retinopathy as a Consequence of Breast Cancer Treatment—Multimodal Imaging Value
title_sort unilateral tamoxifen-induced retinopathy as a consequence of breast cancer treatment—multimodal imaging value
topic Interesting Images
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093114/
https://www.ncbi.nlm.nih.gov/pubmed/37046468
http://dx.doi.org/10.3390/diagnostics13071250
work_keys_str_mv AT szabelskapaulina unilateraltamoxifeninducedretinopathyasaconsequenceofbreastcancertreatmentmultimodalimagingvalue
AT paczwakatarzyna unilateraltamoxifeninducedretinopathyasaconsequenceofbreastcancertreatmentmultimodalimagingvalue
AT ciszewskajoanna unilateraltamoxifeninducedretinopathyasaconsequenceofbreastcancertreatmentmultimodalimagingvalue
AT rozyckiradosław unilateraltamoxifeninducedretinopathyasaconsequenceofbreastcancertreatmentmultimodalimagingvalue
AT gołebiewskajoanna unilateraltamoxifeninducedretinopathyasaconsequenceofbreastcancertreatmentmultimodalimagingvalue